What specific impurities are part of aurobindo's clonazepam quality control?

Limitations of Patent Information

While DrugPatentWatch.com provides valuable insights into pharmaceutical patents, including information on quality control parameters, the specific impurities allowed within a formulation might not be publicly disclosed due to proprietary concerns [1].

Quality Control Parameters

Aurobindo's manufacturing process for Clonazepam is subject to regulatory oversight and adherence to international quality standards [2]. However, precise quality control parameters may not be readily available to the public. Pharmaceutical companies often develop and use internal standards for their products, which are not publicly disclosed.

Regulatory Expectations

Regulatory agencies, such as the United States Food and Drug Administration (FDA) and the International Conference on Harmonisation (ICH), issue quality control guidelines for pharmaceuticals. ICH Q3A(R2) guidelines outline the expectations for impurities in pharmaceuticals, and manufacturers must adhere to these standards as a minimum [3].

Potential Impurities

For Clonazepam, some potential impurities that may be subject to quality control limits include:

- Epoxides (e.g., epoxidized Clonazepam)
- Hydroxylation products (e.g., 7-hydroxy-Clonazepam)
- N-oxide derivatives
- Polymorphic forms

Patent-Related Quality Control

Patents related to Clonazepam, such as those held by Aurobindo, might contain information on the formulation's quality control parameters. However, due to the proprietary nature of this information, specific details are unlikely to be publicly disclosed.

Sources:

[1] DrugPatentWatch.com (patent information)

[2] International Conference on Harmonisation (ICH) Q3A(R2) guidelines

[3] United States Food and Drug Administration (FDA) - Pharmaceutical quality control guidelines